The federal government’s recently approved 340B rebate pilot could reshape one of hospitals’ most relied-on drug discount programs, replacing upfront savings with delayed reimbursements and forcing covered entities to shoulder new financial and administrative risks. As the Jan. 1 start…
Pharmacy
Fresenius Kabi USA is voluntarily recalling three lots of famotidine injection vials due to out-of-specification endotoxin results. Famotidine injection is approved for some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, according to a Nov. 7 FDA recall alert.…
In the closing months of 2025, President Donald Trump’s effort to reshape how Americans pay for prescription drugs has taken clearer form. What started as a campaign threat to slap tariffs on pharmaceutical imports has evolved into a series of…
Pfizer has agreed to acquire weight-loss drugmaker Metsera in a transaction that could exceed $10 billion. Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront, along with a contingent value right worth up to $20.65…
Intellia Therapeutics temporarily paused dosing and screening for its phase 3 Magnitude and Magnitude-2 trials of Nex-z following a patient hospitalization, according to an Oct. 27 news release. The patient, who had been hospitalized with severe liver-related side effects, has…
Advertisement
Mark Cuban Cost Plus Drug Co. has added Starjemza, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab), to its portfolio. The company, co-founded by billionaire entrepreneur Mark Cuban, is offering two strengths of the biosimilar at $360 per syringe, plus…
A new analysis has raised concerns about the Cigna Group’s drug pricing strategy, finding that one of its subsidiaries, Quallent Pharmaceuticals, often charges more for generic medications than competing suppliers, according to a Nov. 7 report from Bloomberg. The review…
Texas Attorney General Ken Paxton has filed a second legal action against Kenvue and Johnson & Johnson, seeking to block a $400 million dividend payout that he argues would hinder the state’s’ ability to recover potential civil penalties tied to…
CMS is launching a pilot program aimed at lowering prescription drug costs in Medicaid by aligning prices with those paid in other developed countries. The program is set to begin in January. “CMS is making a historic commitment to driving…
The FDA awarded six additional products a Commissioner’s National Priority Voucher, bringing the total number of recipients to 15, according to a Nov. 6 news release. The pilot program aims to reduce drug review timelines to as short as two…